169 related articles for article (PubMed ID: 4629252)
1. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies.
Bjornson AB; Michael JG
Infect Immun; 1972 May; 5(5):775-82. PubMed ID: 4629252
[TBL] [Abstract][Full Text] [Related]
2. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. I. Interaction between immunoglobulins, heat-labile serum factors, and phagocytic cells in the killing of bacteria.
Bjornson AB; Michael JG
Infect Immun; 1971 Oct; 4(4):462-7. PubMed ID: 5005303
[TBL] [Abstract][Full Text] [Related]
3. Role of antibody in infections due to Pseudomonas aeruginosa.
Young LS
J Infect Dis; 1974 Nov; 130 Suppl(0):S111-8. PubMed ID: 4213568
[No Abstract] [Full Text] [Related]
4. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.
Fick RB; Naegel GP; Squier SU; Wood RE; Gee JB; Reynolds HY
J Clin Invest; 1984 Jul; 74(1):236-48. PubMed ID: 6429195
[TBL] [Abstract][Full Text] [Related]
5. Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages.
Reynolds HY; Kazmierowski JA; Newball HH
J Clin Invest; 1975 Aug; 56(2):376-85. PubMed ID: 807599
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.
Pier GB; Thomas D; Small G; Siadak A; Zweerink H
Infect Immun; 1989 Jan; 57(1):174-9. PubMed ID: 2491835
[TBL] [Abstract][Full Text] [Related]
7. Factors in human serum promoting phagocytosis of Pseudomonas aeruginosa. I. Interaction of opsonins with the bacterium.
Bjornson AB; Michael JG
J Infect Dis; 1974 Nov; 130 Suppl(0):S119-26. PubMed ID: 4214223
[No Abstract] [Full Text] [Related]
8. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
Young LS
J Infect Dis; 1972 Sep; 126(3):277-87. PubMed ID: 4626510
[No Abstract] [Full Text] [Related]
9. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
Collins MS; Ladehoff DK; Mehton NS; Noonan JS
FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
[TBL] [Abstract][Full Text] [Related]
10. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
[TBL] [Abstract][Full Text] [Related]
12. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody.
Schreiber JR; Pier GB; Grout M; Nixon K; Patawaran M
J Infect Dis; 1991 Sep; 164(3):507-14. PubMed ID: 1831226
[TBL] [Abstract][Full Text] [Related]
13. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions.
Lieberman MM; McKissock DC; Wright GL
Infect Immun; 1979 Feb; 23(2):509-21. PubMed ID: 106013
[TBL] [Abstract][Full Text] [Related]
14. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection.
Moody MR; Kessel RW; Young VM; Fiset P
Infect Immun; 1978 Sep; 21(3):905-13. PubMed ID: 101467
[TBL] [Abstract][Full Text] [Related]
15. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
Hatano K; Goldberg JB; Pier GB
Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
[TBL] [Abstract][Full Text] [Related]
16. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.
Pollack M; Koles NL; Preston MJ; Brown BJ; Pier GB
Infect Immun; 1995 Nov; 63(11):4481-8. PubMed ID: 7591089
[TBL] [Abstract][Full Text] [Related]
17. Protective mechanism of the immune response to a ribosomal vaccine from Pseudomonas aeruginosa. II. In vitro bactericidal and opsonophagocytic studies with specific antiserum.
Lieberman MM; Frank WJ; Brady AV
J Surg Res; 1988 Mar; 44(3):251-8. PubMed ID: 3125389
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of serum from cystic fibrosis patients for Pseudomonas aeruginosa.
Penketh AR; Pitt TL; Hodson ME; Batten JC
J Med Microbiol; 1983 Nov; 16(4):401-8. PubMed ID: 6417338
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.
Fick RB; Naegel GP; Matthay RA; Reynolds HY
J Clin Invest; 1981 Oct; 68(4):899-914. PubMed ID: 6793632
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.
Fick RB; Olchowski J; Squier SU; Merrill WW; Reynolds HY
Am Rev Respir Dis; 1986 Mar; 133(3):418-22. PubMed ID: 3082264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
